← Back to Clinical Trials
Recruiting NCT06756230

NCT06756230 Downhill Walking in IPF

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06756230
Status Recruiting
Phase
Sponsor Saglik Bilimleri Universitesi
Condition Idiopathic Pulmonary Fibrosis (IPF)
Study Type INTERVENTIONAL
Enrollment 34 participants
Start Date 2025-05-13
Primary Completion 2027-02-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Pulmonary RehabilitationDownhill WalkingTreadmill Walking without incline

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 34 participants in total. It began in 2025-05-13 with a primary completion date of 2027-02-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF. After the initial assessment, patients will be randomized into two groups: downhill walking PR group and Standard PR Group.

Eligibility Criteria

Inclusion Criteria: * Having a diagnosis of IPF according to the clinical diagnostic criteria of the American Thoracic Society and/or the European Respiratory Society (ATS-ERS). * Being between the ages of 18 and 75. * Being able to walk on a treadmill. * Having the ability to cooperate. * No change in current medication in the last month. * Not participating in a structured activity program for at least six months. * Accepting the purpose and method of this study voluntarily and give informed consent for the study. Exclusion Criteria: * Presence of physical or mental impairment that prevents informed consent or compliance with the protocol. * Inability to attend more than 20% of pulmonary rehabilitation sessions. * Presence of major cardiovascular disease (coronary artery disease, uncontrolled hypertension, arrhythmias, or heart failure). * Presence of existing orthopedic and neuromuscular exercise limitations. * Acute exacerbation

Contact & Investigator

Central Contact

Esra PEHLIVAN, Associate Professor

✉ fztesrakambur@yahoo.com

📞 02164189616

Frequently Asked Questions

Who can join the NCT06756230 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Idiopathic Pulmonary Fibrosis (IPF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06756230 currently recruiting?

Yes, NCT06756230 is actively recruiting participants. Contact the research team at fztesrakambur@yahoo.com for enrollment information.

Where is the NCT06756230 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT06756230 clinical trial?

NCT06756230 is sponsored by Saglik Bilimleri Universitesi. The trial plans to enroll 34 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology